Alpha Cognition (ACOG) vs AN2 Therapeutics (ANTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Alpha Cognition (ACOG) over the past year, gaining 254.8% versus a gain of 19.4%. Alpha Cognition is the larger company by market cap ($196.9 million vs $166.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | ANTX |
|---|---|---|
| Share price | $9.04 | $4.40 |
| Market cap | $196.87M | $166.04M |
| 1-day change | 0.00% | -5.98% |
| YTD return | +39.08% | +285.96% |
| 1-year return | +19.42% | +254.84% |
| EPS (TTM) | $-1.32 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $7.19 |
| 52-week low | $4.50 | $1.00 |
| Distance from 52-week high | -10.85% | -38.80% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +99.12% | +104.55% |
| Average volume | 125.72K | 240.21K |
| Shares outstanding | 21.78M | 37.74M |
| Employees | 71 | 21 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed ACOG by 235.4 percentage points over the past year.
- The two companies sit in different sectors: Alpha Cognition in Healthcare and AN2 Therapeutics in Health Care.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ACOG vs ANTX FAQ
Which is bigger, Alpha Cognition or AN2 Therapeutics?
Alpha Cognition (ACOG) is larger, with a market capitalization of $196.87M compared with $166.04M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ACOG or ANTX?
ANTX returned +254.84% over the past 12 months, compared with +19.42% for ACOG (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and AN2 Therapeutics in the same industry?
No. Alpha Cognition is in the Healthcare sector, while AN2 Therapeutics is in Health Care.